Skip to main content
. 2020 Jul 15;245(15):1395–1403. doi: 10.1177/1535370220942474

Figure 2.

Figure 2.

JANEX-1 alleviated PDGF-induced PVSMCs proliferation. PVSMCs were treated with 20 ng/mL PDGF or not, and then treated with 20, 50 μM and 100 μM JANEX-1 or not, subsequently, cell viability was monitored by CCK8 assay. (a) JANEX-1 did not inhibit PVSMCs proliferation under normal conditions. (b) JANEX-1 dose-dependently suppressed PDGF-induced PVSMCs proliferation. (c) 50 μM JANEX alleviated PDGF-induced PCNA expression in PVSMCs. Samples derived from the same experiment and gels/blots were processed in parallel. Data are presented as the mean ± SEM (n = 4). *P < 0.05 vs. control group. #P < 0.05 vs. PDGF group. JANEX-1 L, 20 μM; JANEX-1 M, 50 Μm; JANEX-1 H, 100 Μm.